APSARD January 1 - 2024 Supporting materials POSTER: 52-Week Open-Label Safety and Tolerability of Centanafadine Sustained Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder POSTER: Patient-Reported Adult ADHD Symptom Improvements With Centanafadine Sustained Release Correlate With Objective Clinician-Based Efficacy Measures POSTER: Centanafadine Sustained Release Is Efficacious in Patients With Adult ADHD, Regardless of Their Treatment History POSTER: A Thorough QT Study Using C-QTc to Evaluate the Effects of Centanafadine on Cardiac Repolarization POSTER: Centanafadine Sustained Release Is Efficacious in the Treatment of Adult ADHD Across Disease Severities
